Return Home

IA2030 Scorecard — 

Global View

Impact Goal 1: Prevent Disease

Saves Lives

What Does this Indicator Measure?

Model estimates project the number of lives that will be saved from 2021-2023 by achieving IA2030's aspirational coverage targets for WHO-recommended vaccines. Estimates are included for global and regional deaths prevented through the administration of vaccines against 14 diseases. A mid-decade update will add deaths averted by vaccines against a dozen more diseases, including COVID-19, to the projections.

How Will Progress be Measured?

The target is to reach 50 million total deaths averted during 2021-2023. A 2019 baseline was estimated at 4.2 million deaths averted in that year. This indicator will be on track toward the 2030 target if on average 5 million deaths are averted each year.

Number of future deaths averted through immunization—Global

If target is reached, 50 million total future deaths will be averted during 2021-2030 and an average of 5 million deaths will be averted each year.

Summary Table

Streptococcus pneumoniae136,550
TB (BCG)115,980
Yellow fever139,086
Hepatitis B1,323,418
Definition: Total number of future deaths averted from 2021-2030, based on the IA2030 coverage scenario.
Measurement approach: A modeling approach is used to project the number of deaths averted at the global and regional levels by achieving aspirational coverage targets for IA2030. These targets are also aligned with the Impact Goal indicator 3.1- vaccination coverage across the life course. The initial scope focuses on 14 pathogens, which will be expanded to update the estimates at the midpoint of IA2030.

2021-2030: Hepatitis B, Hib, HPV, JE, measles, MenA, Streptococcus pneumoniae, rotavirus, rubella, yellow fever, diphtheria, tetanus, pertussis, TB (BCG)

By 2025: Polio, typhoid, influenza, cholera, multivalent meningitis, COVID-19, varicella, dengue, mumps, rabies, hepatitis A, hepatitis E, and other new vaccines.